Cevimeline

Cevimeline
Clinical data
Trade names Evoxac
AHFS/Drugs.com Monograph
MedlinePlus a608025
Pregnancy
category
  • C
Routes of
administration		 By mouth (capsules)
ATC code N07AX03 (WHO)
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Protein binding <20%
Identifiers
CAS Number 107233-08-9 YesY
PubChem (CID) 83898
DrugBank DB00185 YesY
ChemSpider 75707 YesY
UNII K9V0CDQ56E YesY
KEGG D07667 YesY
ChEBI CHEBI:3568 N
ChEMBL CHEMBL1201267 N
Chemical and physical data
Formula C10H17NOS
Molar mass 199.31308 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Cevimeline (trade name Evoxac) is a parasympathomimetic and muscarinic agonist,[1] with particular effect on M1 and M3 receptors. It is used in the treatment of dry mouth and especially associated with Sjögren's syndrome.

Mechanism of action

By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

Side effects

Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.[2]

Contraindications include asthma and angle closure glaucoma.

See also

References

  1. ↑ Ono M, Takamura E, Shinozaki K, et al. (July 2004). "Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study". Am. J. Ophthalmol. 138 (1): 6–17. doi:10.1016/j.ajo.2004.02.010. PMID 15234277.
  2. ↑ MedicineNet: Cevimeline. Accessed 10/12/2007
This article is issued from Wikipedia - version of the 10/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.